Pasithea Therapeutics Corp.
- KTTA
- NASDAQ
- Biotechnology
- Neuro/Psychiatric Drug Development
- Clinical-Stage Biotech
$0.43
Today +1.71%Quote Oct 19, 2026, 03:17 PM UTC
−17.11%over the last month
Max drawdown −21.8%From 1-month high −19.8%3 months −11.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$14.3M
Quote Oct 19
Next earnings
Nov 12
Expected, not confirmed
Analyst target
$3.00
+602.2% from here
Floor
$0.42
1.2% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KTTAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
5
Founded
2020